<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> type 1 (AT1) receptor blockers decrease <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> by mechanisms dependent on and independent of arterial blood pressure in hypertensive rats and AT1-R knockout mice, respectively </plain></SENT>
<SENT sid="1" pm="."><plain>However, the detailed mechanisms underlying the effects of AT1 receptor blockers remain unclear </plain></SENT>
<SENT sid="2" pm="."><plain>AIMS: To elucidate the systemic and focal effects of AT1 receptor blockers against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in in-vivo and in-vitro studies </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Normotensive Wistar rats were treated for 2 weeks with 0.5 or 1 mg/kg <z:chebi fb="0" ids="3347">candesartan</z:chebi> cilexetil and then subjected to 2-h middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>-reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Human umbilical endothelial cells were stimulated with the active form of <z:chebi fb="0" ids="3347">candesartan</z:chebi> and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> in the absence and presence of an <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 2 (AT2) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In <z:chebi fb="0" ids="3347">candesartan</z:chebi>-pretreated hypotensive and nonhypotensive rats, blood pressure was moderately increased during middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and fell gradually to the baseline after the reperfusion; it remained elevated in the control even after the reperfusion occlusion </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi> treatment resulted in a decrease in the cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and oxidative damage, the hypoxic status was improved, and the expression of repair-associated and growth-associated proteins in the cortical penumbra was augmented </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi> also increased the eNOS <z:chebi fb="2" ids="33699">mRNA</z:chebi> level and the lumen size of the middle cerebral artery </plain></SENT>
<SENT sid="8" pm="."><plain>In human umbilical endothelial cells, <z:chebi fb="0" ids="3347">candesartan</z:chebi> increased the eNOS protein level AT2-R dependently, inhibited the expression of <z:chebi fb="0" ids="25523">nicotinamide adenine dinucleotide phosphate</z:chebi> oxidase subunits and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>-induced intracellular reactive oxygen species and nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi>, and promoted the extracellular release of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi>, suggesting that it augmented the bioavailability of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Among the mechanisms <z:chebi fb="0" ids="3347">candesartan</z:chebi> exerts in its protection against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, restoration of endothelial function may represent an attractive therapeutic goal to address <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>